|Bid||0.0000 x 800|
|Ask||0.0000 x 3000|
|Day's Range||1.1800 - 1.2699|
|52 Week Range||0.7600 - 10.8700|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.75|
Pain Therapeutics Inc. said Wednesday it's changing its name and ticker to better reflect its focus on developing drugs for neurodegenerative diseases such as Alzheimer's. The company will be named Cassava Sciences Inc. with immediate effect. From March 28, it will start trading on Nasdaq under the new ticker symbol "SAVA." The company is currently in a phase 2 testing of a drug candidate aimed at treating Alzheimer's, that does not seek to clear amyloid from the brain, but rather to stabilize a critical protein in the brain. It is also working to develop a biomarker/diagnostic to detect Alzheimer's using a simple blood test. Shares rose 1.7% in premarket trade, but have fallen 82.2% in the last 12 months, while the S&P 500 has gained 7.9%.
Beginning March 28, 2019, Cassava Sciences will trade on NASDAQ under the new ticker symbol: SAVA. Cassava Sciences is in Phase II clinical testing with a new drug candidate to treat patients with Alzheimer’s disease. The Company’s Phase II study is being conducted with scientific and financial support from the National Institutes of Health (NIH).
AUSTIN, Texas, March 25, 2019 -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today reported financial results for the year ended December 31, 2018. Net loss in 2018 was $6.6.
If you own shares in Pain Therapeutics, Inc. (NASDAQ:PTIE) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
Back to Brussels, May Says No Support for Second Brexit Referendum British Prime Minister Theresa May, who somehow is still the Prime Minister of the United Kingdom despite being defeated in almost every critical legislative vote surrounding Brexit which she was brought aboard to deliver, is going back to Brussels to renegotiate the Irish backstop, […] The post Market Update: May Back to Brussels, BP Gushes Oil, Iron Spike, Pain Feels Pain appeared first on Market Exclusive.
Shares of Pain Therapeutics Inc. fell 20% in premarket trade Tuesday, after the company accused the Food and Drug Administration of making basic math errors and other mistakes in a meeting to discuss its Remoxy abuse-deterrent gel formulation of the painkiller oxycodone. In an unusually critical statement, the company said it is no closer to product approval today than it was more than a year ago. "REMOXY remains an odyssey without a homecoming," Chief Executive Remi Barbier said in the statement. "We had hoped for a fair, neutral and impartial review of the REMOXY data. Instead, we walked out of this meeting feeling a bit disoriented by FDA's lack of transparency, clarity or helpfulness. It's a rare occasion when two parties can't agree on simple math. We can't work with shambolic regulations. This is not how you win support for innovation." Remoxy is Pain Therapeutics' lead pipeline candidate that has already gone through a Phase III trial that met its primary endpoint of statistical significance. But the company said its abuse-deterrent properties are subject to a difference of opinion, with the FDA insisting as long as the drug can be extracted, even if it requires equipment and a lot of time, it is a risk for patients. "We are unable to follow the logic by which a drug product should never release drug," said Barbier. "More generally, as the regulatory requirements for REMOXY have changed frequently and suddenly over time, we have experienced significant delays and have incurred unanticipated expenses related to the overall REMOXY development program." Pain Therapeutics' shares have fallen 80% in the last 12 months, while the S&P 500 has gained 2.9%.
Pain Therapeutics, Inc. (PTIE), a clinical-stage drug development company, today announced feedback from a meeting held January 31, 2019 with the U.S. Food and Drug Administration (FDA) regarding the drug candidate, REMOXY ER. REMOXY is the trade name for a new type of abuse-deterrent, extended-release gel formulation of oxycodone (CII) with physical/chemical properties intended to deter abuse. As previously disclosed, we requested this meeting to resolve disagreement around comments and conclusions made by FDA in 2018 during a regulatory review of a New Drug Application (NDA) for REMOXY.
Pain Therapeutics, Inc. (PTIE), a drug development company, announced today it has entered into an academic collaboration with UT Austin in support of a product candidate aimed at pain management, abuse and addiction. The collaboration brings together the Company and UT Austin’s respective scientific expertise and capabilities, with a focus on validating a new technological innovation.
Pain Therapeutics, Inc. (PTIE), a clinical-stage drug development company, announced today it has been awarded $1.5 million in research funding from the National Institutes of Health (NIH). Today’s grant award is intended to support, over the next eighteen months, the Company’s on-going development of new technology to detect Alzheimer’s disease with a simple blood test. NIH research grants are paid out in increments based on milestone-based technical progress. Today’s $1.5 million award is part of a milestone-based research grant previously awarded to Pain Therapeutics by the NIH and announced in September 2017. The NIH's National Institute on Aging awarded today’s research grant to Pain Therapeutics following an in-depth evaluation of its technology for scientific and technical merit, and technical progress made to date.
Pain Therapeutics, Inc. (PTIE), a clinical-stage drug development company, today announced two new publications for its drug candidate, REMOXY ER (extended-release oxycodone). REMOXY is the trade name for a new type of abuse-deterrent, twice-daily capsule gel formulation of oxycodone. REMOXY has physical/chemical properties intended to deter abuse. “For years, opioid drugs were heavily marketed, inappropriately prescribed and lightly regulated, creating ideal conditions for an opioid epidemic,” said Remi Barbier, President & CEO.
Pain Therapeutics, Inc. (PTIE) today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). This voluntary filing with the SEC is intended to register for resale common stock underlying previously issued warrants. The Company’s Form S-1 registration statement has been filed with the SEC but has not yet become effective.
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, announced today the initiation of a Phase II study to evaluate PTI-125 as a potential first line treatment in patients with Alzheimer’s disease. This clinical study is supported by a research grant award from the National Institute on Aging (NIA), the primary Federal agency supporting new research in Alzheimer’s disease. “There is a profound and timely need to develop new drugs for Alzheimer’s,” said Remi Barbier, President & CEO.
Every investor in Pain Therapeutics Inc (NASDAQ:PTIE) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that it has petitioned the Food & Drug Administration (FDA) regarding a Complete Response Letter (CRL) for REMOXY issued August 2018. The FDA and the Company have agreed to meet in-person on January 31, 2019 to discuss this matter. REMOXY is the proposed trade name for a new type of abuse-deterrent, twice-daily, capsule gel formulation of oxycodone. REMOXY has physical/chemical properties intended to deter abuse, compared to marketed extended-release oxycodone products. “The opioid crisis rages on, yet deficiencies of certain prescription opioid drugs are still with us,” said Remi Barbier, President & CEO of Pain Therapeutics. “It’s a matter of national interest to address these deficiencies head-on, even if it means taking certain opioid drugs off the market.
shed 53% to $1.35 on Thursday, Oct. 4, after the company said it was filing an "administrative appeal" with the Federal Drug Administration after the agency rejected a drug the company was developing. In August, the FDA rejected Pain Therapeutics' Remoxy drug, an oxycodone designed to discourage most methods of tampering linked to opioid abuse, because the benefits of the drug weren't great enough to justify the risks. The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, part of the FDA, voted 14 to 3 against the drug.
DYAI has over $40 million in the bank, a stock buyback agreement, and entered into an additional fully funded research collaboration with Sanofi-Aventis to test the feasibility of using C1 to produce multiple genes for vaccine and drug applications. For those that do not know Sanofi-Aventis is over a $100 Billion company that trades on the New York Stock Exchange. DYAI currently has assets on its balance sheet of over $49 Million while only has a market cap of $46 Million.
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Both Pain Therapeutics and VistaGen Therapeutics were two biotech stocks seeing big gains on Wednesday. While Pain Therapeutics had no news to explain a 200% ...